Abstract
Idiopathic Pulmonary Fibrosis (IPF) is a chronic interstitial lung disease which results in end-stage fibrosis. The pathogenesis is believed to be related to a dysregulation in cross-talk between inflammatory and structural cells, mediated by various cytokines, chemokines and growth factors, which are responsible for the maintenance of tissue homeostasis and which coordinate the response to injury. The large number of mediators involved and the complexity of their interaction makes it difficult to identify the factors responsible for initiation of fibrogenesis and progression to chronicity. Whether a mediator ’ s presence in fibrotic lung is as a result of tissue injury or if it playsan active role in disease onset and progression has been partly answered by the use of transient and / or permanent transgenic and gene knock-out approaches to over-express single factors at a time. Chemokines such as interleukin-8 (IL-8), RANTES, IP-10, MIG or lymphotactin, do not appear to induce fibrosis when over-expressed in rodent lung. Amongst many tested, four cytokines and growth factors have been found to be pro-fibrotic; IL-1β, which demonstrates marked inflammation, tissue damage and chronic fibrosis, TNF-?, which induces inflammation and mild fibrosis, and GM-CSF, which induces moderate inflammation and fibrosis. A common finding with these cytokines are increased lung TGF-β levels, proportionate to the degree of fibrosis generated, while TGF-β itself causes minor inflammation but marked progressive chronic fibrosis. A growth factor ‘downstream’ from the pro-fibrotic effects of TGF-β, CTGF, is a likely critical mediator. However, over-expression of CTGF produces only mild and reversible fibrosis.
Keywords: Fibrogenic Cytokines, cytokines, RANTES, lymphotactin, homeostasis
Current Pharmaceutical Design
Title: Re-evaluation of Fibrogenic Cytokines in Lung Fibrosis
Volume: 9 Issue: 1
Author(s): Margaret Kelly, Martin Kolb, Phillipe Bonniaud and Jack Gauldie
Affiliation:
Keywords: Fibrogenic Cytokines, cytokines, RANTES, lymphotactin, homeostasis
Abstract: Idiopathic Pulmonary Fibrosis (IPF) is a chronic interstitial lung disease which results in end-stage fibrosis. The pathogenesis is believed to be related to a dysregulation in cross-talk between inflammatory and structural cells, mediated by various cytokines, chemokines and growth factors, which are responsible for the maintenance of tissue homeostasis and which coordinate the response to injury. The large number of mediators involved and the complexity of their interaction makes it difficult to identify the factors responsible for initiation of fibrogenesis and progression to chronicity. Whether a mediator ’ s presence in fibrotic lung is as a result of tissue injury or if it playsan active role in disease onset and progression has been partly answered by the use of transient and / or permanent transgenic and gene knock-out approaches to over-express single factors at a time. Chemokines such as interleukin-8 (IL-8), RANTES, IP-10, MIG or lymphotactin, do not appear to induce fibrosis when over-expressed in rodent lung. Amongst many tested, four cytokines and growth factors have been found to be pro-fibrotic; IL-1β, which demonstrates marked inflammation, tissue damage and chronic fibrosis, TNF-?, which induces inflammation and mild fibrosis, and GM-CSF, which induces moderate inflammation and fibrosis. A common finding with these cytokines are increased lung TGF-β levels, proportionate to the degree of fibrosis generated, while TGF-β itself causes minor inflammation but marked progressive chronic fibrosis. A growth factor ‘downstream’ from the pro-fibrotic effects of TGF-β, CTGF, is a likely critical mediator. However, over-expression of CTGF produces only mild and reversible fibrosis.
Export Options
About this article
Cite this article as:
Kelly Margaret, Kolb Martin, Bonniaud Phillipe and Gauldie Jack, Re-evaluation of Fibrogenic Cytokines in Lung Fibrosis, Current Pharmaceutical Design 2003; 9 (1) . https://dx.doi.org/10.2174/1381612033392341
DOI https://dx.doi.org/10.2174/1381612033392341 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bone-Muscle Crosstalk: Unraveling New Therapeutic Targets for Osteoporosis
Current Pharmaceutical Design The Function of LncRNA FTX in Several Common Cancers
Current Pharmaceutical Design Deciphering the Role of microRNAs in Regulation of Immune Surveillance, Self-Tolerance and Allograft Transplant Outcome
Current Stem Cell Research & Therapy Functional Role of Natural Antioxidants in Controlling Oxidative Stress Associated with SARS-CoV-2 Infection
Coronaviruses New Therapies for Patients with Chronic Lymphocytic Leukemia
Current Cancer Therapy Reviews Gammadelta T Lymphocytes Producing IFNγ and IL-17 in Response to Candida Albicans or Mycobacterial Antigens: Possible Implications for Acute and Chronic Inflammation
Current Medicinal Chemistry Leishmaniasis: Prevention, Parasite Detection and Treatment
Current Medicinal Chemistry Acute Respiratory Failure in Obstetric Patients
Current Women`s Health Reviews Exercise Prescription for Post-Menopausal Women with Obesity
Current Women`s Health Reviews Smoking and Obesity Increase Airway Hyperesponsiveness Risk in the Elderly
Current Aging Science Pentraxins: CRP and PTX3 and Cardiovascular Disease
Inflammation & Allergy - Drug Targets (Discontinued) Inflammation in Peripheral Arterial Disease (PAD)
Current Pharmaceutical Design Synthesis of Prenylated Xanthones: An Overview
Current Organic Chemistry Interleukin-7 Biology in HIV Disease and the Path to Immune Reconstitution
Current HIV Research Human Urotensin II Promotes Hypertension and Atherosclerotic Cardiovascular Diseases
Current Medicinal Chemistry Non Steroidal Anti-Inflammatory Drugs and Neurogenesis in the Adult Mammalian Brain
Current Pharmaceutical Design Editorial [Hot topic: Stroke as a Target in Medicinal Chemistry and Drug Discovery (Guest Editor: Antonino Tuttolomondo)]
Current Topics in Medicinal Chemistry Chemoresistance of Cancer Cells: Oncogenic Mutation of the p53 Tumor Suppressor Gene
Current Signal Transduction Therapy Stimuli-induced Pulsatile or Triggered Release Delivery Systems for Bioactive Compounds
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Clinical Significance of Pleiotropic Effects of Statins: Lipid Reduction and Beyond
Current Medicinal Chemistry